Lyn Rosenbrier Ribeiro

Lyn Rosenbrier Ribeiro currently serves as Director and Discovery Safety Lead at Grünenthal Group since December 2021. Previously, Lyn worked at UCB as Non-Clinical Safety Lead and Associate Director, providing preclinical safety leadership across various therapeutic areas. Lyn's consultancy experience includes R2 Pharmacology Ltd and Medicines Discovery Catapult, where project management and drug discovery consultancy were key responsibilities. Lyn spent a significant period at AstraZeneca in various roles, including Mechanistic Pharmacology Lead, focusing on safety and secondary pharmacology, and contributing to drug discovery projects for arthritis treatments. Early career experience includes positions at Covance and Aventis, with foundational education in Biochemistry (PhD) from The University of Manchester and a BSc in Biomedical Sciences from the University of Bradford.